ArticleNutrients2025
Integrated Transcriptomics and Network Pharmacology Reveal the Mechanism of Poplar-Type Propolis on the Mouse Mastitis Model.
Article in Nutrients, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
BACKGROUND/
objectivesMastitis adversely affects human lactation, and there is a need for effective natural therapeutic agents. Poplar-type propolis is known for its anti-inflammatory properties, but its protective effects and mechanisms against mastitis remain unclear. This study aimed to investigate the therapeutic potential and underlying mechanisms of ethanol extract of Chinese propolis (EECP) against lipopolysaccharide (LPS)-induced mastitis.
methodsAn integrated approach combining network pharmacology and transcriptomics was employed. In vivo validation was conducted using an LPS-induced mouse mastitis model in female BALB/c mice. Molecular docking was used to confirm interactions between key EECP components and core targets.
resultsNetwork pharmacology identified 36 potential targets, primarily involved in inflammatory and immune pathways such as tumor necrosis factor (TNF), nuclear factor kappa B (NF-κB), janus kinase-signal transducers and activators of transcription (JAK-STAT), phosphatidylinositol 3-kinase/protein kinase B (PI3K-AKT), and interleukin (IL)-17 pathways. In vivo experiments demonstrated that EECP significantly alleviated LPS-induced histopathological damage, reduced neutrophil infiltration, and decreased the expression of proinflammatory cytokines (
conclusionsEECP exerts protective effects against LPS-induced mastitis through the synergistic actions of multiple components. This study lays the preclinical foundation for considering poplar-type propolis as a candidate for the prevention or alleviation of mastitis, meriting further evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.